Isentress 600mg film-coated tablets
raltegravir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
Contents of the pack
What Isentress is
Isentress contains the active substance raltegravir. Isentress is an antiviral medicine that acts against the human immunodeficiency virus (HIV). This is the virus that causes acquired immune deficiency syndrome (AIDS).
How Isentress works
The virus produces an enzyme called HIV integrase, which helps the virus to enter the cells of the body and multiply. Isentress prevents this enzyme from working. When used with other medicines, Isentress can reduce the amount of HIV in the blood (this is called your “viral load”) and increase the number of CD4 cells (a type of white blood cell that plays an important role in keeping the immune system healthy to help fight infection). By reducing the amount of HIV in the blood, it can improve the functioning of your immune system. This means your body can fight better against the infection.
When Isentress should be used
Isentress 600 mg film-coated tablets are used to treat adults and pediatric patients weighing at least 40 kg who are infected with HIV. Your doctor has prescribed Isentress to help control the HIV infection you have.
Do not take Isentress:
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start taking Isentress.
Remember that Isentress does not cure HIV infection. This means you can still get illnesses or infections related to HIV. You must keep seeing your doctor regularly while taking this medicine.
Mental health problems
Tell your doctor if you have a history of depression or mental health problems. Depression, including thoughts and behaviors of suicide, has been seen in some patients while taking this medicine, especially in patients with a previous history of depression or mental health problems.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immune system suppression, increased body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, discomfort, and pain (especially in the hip, knee, and shoulder) and difficulty moving. If you experience any of these symptoms, see your doctor.
Liver problems
Tell your doctor, pharmacist, or nurse if you have had liver problems in the past, including hepatitis B or C. Your doctor may assess the severity of your liver disease before deciding if you can take this medicine.
Infections
If you notice any symptoms of infection, such as fever and/or feeling unwell, tell your doctor, pharmacist, or nurse immediately. Some patients with advanced HIV infection who have previously had opportunistic infections may show signs and symptoms of inflammation due to previous infections soon after starting HIV treatment. It is believed that these symptoms are due to the improvement of the body's immune response, which allows the body to fight infections that it may have had but were not showing obvious symptoms.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also appear after you have started taking medicines for the treatment of your HIV infection. Autoimmune disorders may appear many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremors, or hyperactivity, tell your doctor immediately to receive the necessary treatment.
Muscle problems
Contact your doctor, pharmacist, or nurse immediately if you notice unexplained muscle pain, tenderness, or muscle weakness while taking this medicine.
Skin problems
Contact your doctor immediately if you develop a rash. Serious and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking this medicine.
Other medicines and Isentress
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.
Isentress may interact with other medicines. Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take:
Carry a list of all your medicines to show your doctor and pharmacist.
Taking Isentress with food and drinks
See section 3.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Do not drive, operate machinery, or ride a bicycle if you feel dizzy after taking this medicine.
Isentress contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Isentress contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. If you are not sure, check with your doctor, pharmacist, or nurse. Isentress should be used in combination with other medicines for HIV infection.
How much to take
Adults, children, and adolescents weighing at least 40 kg
The recommended dose is 1,200 mg taken as two 600 mg tablets by mouth once daily.
Do not chew, crush, or split the tablets as this may alter the amount of medicine in your body. You can take this medicine with or without food or drinks.
Isentress is also available as a 400 mg tablet, chewable tablet, and oral suspension.
Do not switch between the 600 mg tablet, 400 mg tablet, chewable tablet, or oral suspension without first consulting your doctor, pharmacist, or nurse.
If you take more Isentress than you should
Do not take more tablets than your doctor has recommended. If you take more tablets than recommended, talk to your doctor.
If you forget to take Isentress
If you stop taking Isentress
It is important that you take Isentress exactly as your doctor has told you. Do not change the dose or stop taking this medicine without first consulting your doctor, pharmacist, or nurse. Do not stop taking it because:
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects– these are uncommon (may affect up to 1 in 100 people)
See a doctor immediately if you notice any of the following side effects:
See a doctor immediately if you notice any of the above side effects.
Common: the following side effects may affect up to 1 in 10 people
Uncommon: the following side effects may affect up to 1 in 100 people
Other side effects in children and adolescents
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Isentress Composition
The active ingredient is raltegravir. Each film-coated tablet contains 600 mg of raltegravir (potassium).
The other ingredients are: microcrystalline cellulose, hypromellose 2910, sodium croscarmellose, and magnesium stearate. Additionally, the coating contains the following inactive ingredients: lactose monohydrate, hypromellose 2910, titanium dioxide, triacetin, yellow iron oxide, and black iron oxide. The tablet may also contain traces of carnauba wax.
Product Appearance and Package Contents
The 600 mg film-coated tablet is oval in shape, yellow in color, with the MSD corporate logo and the inscription "242" embossed on one side and the other side is smooth.
Two package sizes are available: packages of 1 bottle of 60 tablets and multiple packages containing 3 bottles of 60 tablets each. The bottle contains a desiccant.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For further information on this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 2780 247 |
| Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 |
Denmark MSD Danmark ApS Tel: +45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 | Norway MSD (Norge) AS Tel: +47 32 20 73 00 |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 |
France MSD France Tel: +33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 |
Iceland Vistor ehf. Tel: + 354 535 7000 | Slovak Republic Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Finland MSD Finland Oy Tel: +358 (0)9 804 650 |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvia SIA Merck Sharp & Dohme Latvija Tel: + 371 67025300 |
Date of Last Revision of this Leaflet:<{MM/AAAA}><{month AAAA}>.
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ISENTRESS 600 MG FILM-COATED TABLETS – subject to medical assessment and local rules.